Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs Tofacitinib in Active Takayasu Arteritis
NCT05151848Phase 4Recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab and tofacitinib oral solution in Takayasu arteritis (TAK) (2 arms), sponsored by Chinese SLE Treatment And Research Group. Primary endpoint: Percentage of patients with complete response at 78 weeks. Started Jan 2022; status: recruiting.
02
Drugs
adalimumabtofacitinib oral solution
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT05151848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151848.